Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Over 30 years of biopharmaceutical industry experience. Former Executive Vice President and Chief Commercial Officer at Incyte. Held senior leadership positions at Amgen and GlaxoSmithKline. Serves on boards of Acadia and argenx SE.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

CYTOKINETICS INC

2025-01-01 · current

Confirmed by public sourceView source

Director

MADRIGAL PHARMACEUTICALS, INC.

2019-01-01 · current

Confirmed by public sourceView source

Director

ACADIA PHARMACEUTICALS INC

2016-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

ACADIA PHARMACEUTICALS INC

Open ACADIA PHARMACEUTICALS INC profile →

Director at ACADIA PHARMACEUTICALS INC

2016-01-01 → End not stated

current · source reported

Observed: 2026-09-25

ACADIA PHARMACEUTI…ACADIA PHARMACEUTICALS INCCYTOKINETICS INCCYTOKINETICS INCMADRIGAL PHARMACEU…MADRIGAL PHARMACEUTICALS, INC.James M. Daly

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingACADIA PHARMACEUTICALS INC director board sourceSupports Board membership, Committee assignments, Director since, Board independence.Open sourceSource 2 · Sec FilingCYTK DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 3 · Sec FilingAMRX DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 4 · Sec FilingMDGL DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:james-m-daly
Record version
public-0

Published evidence records

12 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ACADIA PHARMACEUTICALS INC director board source

    sec filing · Source published: Apr 24, 2026 · Retrieved: May 3, 2026

    Supports 5 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of ACADIA PHARMACEUTICALS INC · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of CYTOKINETICS INC · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Madrigal Pharmaceuticals · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  2. ACAD DEF 14A director slate

    sec filing · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: Apr 24, 2026

  3. Open source

    sec proxy · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at ACADIA PHARMACEUTICALS INC · Claim reviewed: May 16, 2026

  4. CYTK DEF 14A director slate

    sec filing · Source published: Apr 17, 2026 · Retrieved: May 8, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Transactions · Claim reviewed: May 8, 2026

  5. Open source

    sec proxy · Source published: Apr 17, 2026 · Retrieved: May 8, 2026

    Supports 1 claim
    • Professional Role: Director at CYTOKINETICS INC · Claim reviewed: May 16, 2026

  6. AMRX DEF 14A executive officers

    sec filing · Source published: Mar 25, 2026 · Retrieved: May 14, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Amneal Pharmaceuticals, Inc. · Claim reviewed: May 14, 2026
    • Executive title: Executive title: Executive Vice President, Chief Legal Officer and Corporate Secretary · Claim reviewed: May 14, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  7. MDGL DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Nominating/Governance · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  8. Madrigal Pharmaceuticals director board source

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 3, 2026

    Supports 5 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of ACADIA PHARMACEUTICALS INC · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of CYTOKINETICS INC · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Madrigal Pharmaceuticals · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  9. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: May 1, 2026

    Supports 1 claim
    • Professional Role: Director at MADRIGAL PHARMACEUTICALS, INC. · Claim reviewed: May 16, 2026

  10. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of CYTOKINETICS INC · Claim reviewed: May 3, 2026

  11. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Madrigal Pharmaceuticals · Claim reviewed: May 3, 2026

  12. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of ACADIA PHARMACEUTICALS INC · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · CorroboratedIndependent directorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of ACADIA PHARMACEUTICALS INCSupported by 4 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of CYTOKINETICS INCSupported by 3 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of Madrigal PharmaceuticalsSupported by 4 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · CorroboratedBoard role: DirectorSupported by 3 public records3 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 8, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Transactions1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 8, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 8, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive company · Source reportedExecutive at Amneal Pharmaceuticals, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive title · Source reportedExecutive title: Executive Vice President, Chief Legal Officer and Corporate Secretary1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources12 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

    Supports: Board role · Committee assignments

  3. https://www.sec.gov/Archives/edgar/data/1070494/000119312526174163/acad-20260423.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 8, 2026

    Supports: Board role · Committee assignments

  5. https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 8, 2026

    Supports: Director at CYTOKINETICS INC (NASDAQ: CYTK)

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  9. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 1, 2026

    Supports: Director at MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL)

  10. https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  11. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  12. https://www.sec.gov/Archives/edgar/data/1070494/000119312526174163/acad-20260423.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership